Your browser is no longer supported. Please, upgrade your browser.
Plus Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.79 Insider Own0.10% Shs Outstand5.37M Perf Week-12.58%
Market Cap60.19M Forward P/E- EPS next Y-1.40 Insider Trans26.84% Shs Float4.51M Perf Month12.45%
Income-8.20M PEG- EPS next Q-0.41 Inst Own2.30% Short Float3.42% Perf Quarter26.64%
Sales0.30M P/S200.63 EPS this Y32.90% Inst Trans-12.50% Short Ratio0.17 Perf Half Y11.98%
Book/sh0.56 P/B4.84 EPS next Y17.20% ROA-56.20% Target Price- Perf Year38.97%
Cash/sh0.37 P/C7.25 EPS next 5Y- ROE-364.80% 52W Range0.93 - 5.42 Perf YTD34.16%
Dividend- P/FCF- EPS past 5Y- ROI-103.10% 52W High-50.00% Beta0.43
Dividend %- Quick Ratio1.10 Sales past 5Y-51.80% Gross Margin- 52W Low191.08% ATR0.42
Employees12 Current Ratio1.10 Sales Q/Q-100.00% Oper. Margin- RSI (14)45.03 Volatility10.89% 14.61%
OptionableNo Debt/Eq2.10 EPS Q/Q-384.00% Profit Margin- Rel Volume0.30 Prev Close2.61
ShortableYes LT Debt/Eq0.00 EarningsFeb 22 AMC Payout- Avg Volume910.78K Price2.71
Recom1.70 SMA20-12.65% SMA504.08% SMA20012.41% Volume272,623 Change3.83%
Jan-25-21Initiated Ladenburg Thalmann Buy $8
Oct-16-20Initiated Maxim Group Buy $6
Mar-02-21 07:30AM  
Mar-01-21 07:30AM  
Feb-22-21 04:05PM  
Feb-11-21 04:15PM  
Jan-11-21 10:11AM  
Jan-05-21 04:15PM  
Dec-15-20 07:30AM  
Dec-08-20 07:30AM  
Dec-01-20 07:30AM  
Nov-19-20 08:00AM  
Nov-16-20 08:00AM  
Nov-13-20 07:30AM  
Nov-12-20 07:25AM  
Nov-05-20 07:00AM  
Oct-29-20 07:00AM  
Oct-22-20 04:05PM  
Oct-15-20 07:00AM  
Oct-14-20 04:15PM  
Oct-02-20 07:00AM  
Oct-01-20 07:00AM  
Sep-15-20 07:00AM  
Sep-09-20 07:00PM  
Sep-03-20 07:00AM  
Sep-01-20 07:00AM  
Aug-28-20 07:00AM  
Aug-25-20 10:31AM  
Aug-10-20 07:43AM  
Aug-03-20 07:00AM  
Jul-28-20 07:00AM  
Jul-23-20 05:00PM  
Jul-06-20 08:01AM  
May-14-20 04:27PM  
May-12-20 08:57AM  
May-11-20 06:00AM  
May-07-20 04:15PM  
Apr-16-20 04:15PM  
Apr-06-20 07:00AM  
Apr-01-20 07:00AM  
Mar-30-20 04:05PM  
Mar-25-20 05:53PM  
Mar-12-20 07:15AM  
Feb-06-20 05:00PM  
Jan-06-20 07:15AM  
Jan-02-20 04:15PM  
Dec-09-19 07:00AM  
Nov-25-19 07:00AM  
Nov-14-19 04:05PM  
Nov-04-19 07:00AM  
Oct-15-19 09:20AM  
Sep-26-19 04:10PM  
Sep-23-19 12:15PM  
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HEDRICK MARC HChief Executive OfficerDec 10Buy1.992,5004,97513,867Dec 14 06:05 AM
HEDRICK MARC HChief Executive OfficerNov 30Buy2.142,2004,70811,367Dec 02 07:00 AM
Lenk Robert PDirectorAug 25Buy2.493,0007,4653,000Aug 26 06:05 AM
Petersen GregDirectorAug 13Buy2.8010,00028,00020,000Aug 14 06:05 AM
Petersen GregDirectorAug 12Buy2.5210,00025,20010,000Aug 13 06:05 AM
HEDRICK MARC HChief Executive OfficerAug 12Buy2.584,00010,3189,167Aug 13 06:00 AM
HEDRICK MARC HChief Executive OfficerJun 22Buy2.105,00010,5005,167Jun 23 07:10 PM